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Background: Rhizoma Menispermi (RM) is the dried root of Menispermum dauricum DC, which is traditionally used
to treat swelling and pain for sore throat, enteritis and rheumatic arthralgia in the clinic, but its bioactive
compounds remain unclear.
Methods: In this study, RM extract was administered orally to ICR mice followed by challenging with an intratracheal
Pseudomonas aeruginosa suspension. Then mortality, histological features of lung, and inflammatory cytokines were
evaluated. RM treatment significantly ameliorated Pseudomonas aeruginosa-induced acute lung inflammation and
reduced levels of inflammatory mediators. To screen for potential anti-inflammatory constituents of the RM extract, a
simple and rapid method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass
spectrometry (UPLC-Q/TOF MS) coupled with a luciferase reporter assay system to detect nuclear factor-κB (NF-κB)
activity was established.
Results: Using this system, seven potential NF-κB inhibitors were detected, including sinomenine, norsinoacutin,
N-norsinoacutin-β-D-glucopyranoside, 6-O-methyl-laudanosoline-13-O-glucopyranoside, magnoflorine, laurifloline and
dauricinoline. Furthermore, IL-6 and IL-8 assays confirmed the anti-inflammatory effects of these potential NF-κB
inhibitors, in which norsinoacutin, 6-O-methyl-laudanosoline-13-O-glucopyranoside laurifloline, dauricinoline and
N-norsinoacutin-β-D-glucopyranoside were revealed as new NF-κB inhibitors.
Conclusion: This method of UPLC-Q/TOF coupled with the luciferase reporter assay system was initially applied to the
study of RM and was demonstrated to represent a simple, rapid and practical approach to screen for anti-inflammatory
compounds. This study provided useful results for further investigation on the anti-inflammatory mechanism of RM.
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Lung inflammation occurs as a consequence of complex in-
teractions between multiple cell types, cytokines, and media-
tors of the inflammatory network [1]. It can lead to cytokine
production, vascular leakage, and neutrophil influx by acti-
vating the immune system, and the combined response of
local immune cells mediated by cytokines, chemokines and
adhesion molecules contributes to severe lung injury and
mortality [2,3]. NF-κB (nuclear factor-κB) is considered to
play a central role in a variety of acute and chronic inflam-
matory diseases [4]. During inflammation, NF-κB cooperates
with multiple upstream signaling pathways and other signal-
ing molecules by regulating and activating the expression of
multiple cytokines, chemokines and inflammatory mediators
[5,6]. Active NF-κB can enter the nucleus to activate the
transcription of TNF-α (Human tumor necrosis factor
alpha), IL-6 (interleukin-6), IL-8 (interleukin-8) and other
inflammatory factors, which can cause the repeated phos-
phorylation and degradation of IκB, leading the activation of
NF-κB and further increasing the expression of inflamma-
tory cytokines [7,8]. Thus, NF-κB is a key transcription fac-
tor in the inflammatory response, and targeting NF-κB is
increasingly recognized as a fascinating opportunity to de-
velop novel therapeutics for inflammatory disorders.
It is difficult to target the desired lesions when treating
inflammatory disorders using Western drugs, such as cor-
ticosteroids and non-steroidal anti-inflammatory drugs
because inflammation involves many inflammatory media-
tors and pathways that lead to a wide range of physio-
logical changes [9]. Recently, traditional Chinese medicine
(TCM) has drawn more and more attention because of its
multi-component characteristics, including the ability to
affect multiple targets and levels of signaling pathways
and their multiple mechanisms to mitigate inflammation
[10]. A large number of mechanistic studies have been
performed by experts worldwide that demonstrate the im-
portance and necessity of investigating TCM.
Rhizoma Menispermi (RM) is a commonly used herbal
drug in TCM that has been reported to be effective for
clearing away heat, removing toxic material, dispelling
wind and relieving pain, and RM is typically used to treat
swelling and pain for sore throat, enteritis and rheumatic
arthralgia in the clinic. The dried root of Menispermum
dauricum DC (Menispermaceae) is the predominant
source of RM [11]. The primary components of RM are
alkaloids, which principally could be classified as morphi-
nane and aporphine-type alkaloids [12-14]. Presently, the
ingredients magnoflorine, acutumine, acutumidin, acutu-
minine and sinomenine have been extracted and separated
from RM [15]. The anti-inflammatory effect of a water
decoction of RM on mice has been reported [16,17].
Nevertheless, the therapeutic effect of RM on lung inflam-
mation remains uninvestigated, and the bioactive compo-
nents in RM remain unknown.Identifying novel bioactive compounds from TCMs
remains a challenge, although many of these com-
pounds have been demonstrated to be effective based
on modern pharmacological studies and clinical trials.
Traditional methods based on the extraction and isola-
tion of purified compounds to screen for bioactive com-
pounds consume a great deal of time and sample.
Therefore, a rapid and effective screening method is ne-
cessary. Ultra-performance liquid chromatography/
quadrupole time-of-flight mass spectrometry (UPLC/Q-
TOFMS) is being widely applied to analyze and identify
TCM components due to its high peak capacity, high
resolution, greater speed of analysis, and the advantages
of structural information derived from TOFMS (time-
of-flight mass spectrometry) technology for accurate
mass determination [18,19]. Our group has developed
an approach combining UPLC/Q-TOF-MS with a lucif-
erase reporter assay system to rapidly screen for inhibi-
tors of NF-κB, which is a simple and effective strategy
to rapidly screen for anti-inflammatory compounds in
TCM preparations [20].
Pseudomonas aeruginosa is a ubiquitous opportunistic
pathogen [21,22]. It is a gram-negative bacterium which
causes various infections, especially in patients with
compromised host defense mechanisms [23,24]. P. aeru-
ginosa causes a remarkably higher mortality than other
lung infection pathogens and has been categorized as
one of the most pressing threats to the future of human
health by the Infectious Diseases Society of America
[25,26]. P. aeruginosa can colonize in airway epithelium
with its surface appendages such as flagella and pili.
And it produces toxins such as type III secretion pro-
tein, pyocyanin and LPS, and rapidly causes serious lung
inflammation. A comprehensive reaction of immune
cells such as macrophages, neutrophils, and lympho-
cytes mediated by cytokines and chemokines can also
contribute to severe lung injury and mortality. It has
been shown that inflammatory cytokines and chemo-
kines such as TNF-α, IL-1β, IL-6, IL-8, and RANTES
have deleterious effects in the progression and persist-
ence of lung inflammation [27,28].
In this study, the anti-inflammatory effect of RM on lung
inflammation induced by the Pseudomonas aeruginosa
PAK strain was investigated. The bioactive compounds
were screened using UPLC-MS and NF-κB luciferase re-
porter system assays. This study could indicate the potential
anti-inflammatory agents of RM and provide useful results
for further investigation on the anti-inflammatory mechan-
ism of RM at the molecular level.
Methods
Chemicals and materials
Strain PA68 was a clinical isolate from the sputum of a
patient suffering from bronchiectasis [29]. HPLC-grade
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Germany). Deionized water was purified using a Milli-Q
system (Millipore Laboratory, Bedford, MA, USA). RM,
Lot No. 1208076931, was purchased from AnGuo
Changan Limited Company (HeBei, China) and identi-
fied by Professor Tiejun Zhang from the Tianjin Insti-
tute of Pharmaceutical Research. Magnoflorine and
sinomenine were purchased from Yifang S&T (Tianjin,
China). N-norsinoacutin-β-D-glucopyranoside, norsi-
noacutin, dauricinoline laurifloline and 6-O-methyl-lau-
danosoline-13-O-glucopyranoside, were isolated and
purified from RM by our group, which were determined
to be more than 98% pure based on HPLC. TNF-α was
obtained from PeproTech (Rock Hill, NJ). Cefradine
(Cef ) capsules were purchased from Hainan Haili
Pharmaceutical Co., Ltd (Hainan, China). Dexametha-
sone (Dex) was purchased from Sigma Chemical Co.
(St. Louis, MO, USA). CO2 was purchased from Indus-
trial Gas Distribution Co., Ltd., Tianjin hexagonal. Aver-
tin was purchased from Kangkede Technology Co., Ltd
(Tianjin, China). All reagents for cell culture were pur-
chased from Gibco BRL Life Technologies (Rockville,
MD, USA). Lipofectamine 2000 transfection reagent
was obtained from Invitrogen (Carlsbad, CA, USA). All
other reagents used in this study were of analytical
grade.
Animals
ICR mice (male, 18–22 g) were purchased from the Experi-
mental Animal Center of the National Institute for the
Control of Pharmaceutical and Biological Products (Beijing,
China). All Animals were housed in standard conditions
with a normal diet under an ambient temperature of 23–
26°C and 40%-65% relative humidity with a 12 h light/dark
artificial light cycle.
Ethics statement
All experimental protocols carried out conformed to the
Guide for the Care and Use of Laboratory Animal Care
and Use in Research (Ministry of Health, Beijing, China),
and were approved by the Animal Ethics Committee of
Nankai University.
Sample preparation
RM powder (10 g) was added to 10 volumes of water
and decoated for 1 h. The decoction was filtered and
then concentrated to a final concentration of 1 g/mL
(crude drug/decoction).
One gram of RM was lyophilized and sequentially ex-
tracted using 10 mL of petroleum ether, dichloromethane,
ethyl acetate, n-butanol and distilled water. Each fraction
was evaporated in vacuo. Then, the petroleum ether extract
(PEE), dichloromethane extract (DME), ethyl acetate ex-
tract (EAE), n-butanol extract (BUE) and aqueous extract(AQE) were obtained. The extracts were dissolved in a 0.1%
DMSO solution and resuspended in cell-cultured medium
for the luciferase activity assays.
The BUE fraction was dissolved in methanol and fil-
tered using a 0.22 μm filter prior to LC/MS analysis.
P. aeruginosa PAK strain-induced acute lung infection
mouse model
An acute lung infection test was performed using the P.
aeruginosa PAK strain-induced mouse model [21]. The
mice were randomly separated into the following six
groups: control group, model group; low, middle and
high dose RM (RM-L, RM-M and RM-H) groups, and
positive control (Cef ) group. Each group consisted of 10
mice. All mice were treated with the P. aeruginosa PAK
strain, except for the mice in the control group. The
mice in the RM groups were intragastrically adminis-
tered the appropriate dose (1, 3 or 9 g crude drug/kg)
for 7 consecutive days. The positive control and model
group mice were administered Cef (100 mg/kg) and nor-
mal saline, respectively. The P. aeruginosa PAK strain
was cultured in Luria-Bertani medium and resuspended
in sterile PBS at a concentration of 109 colony-forming
units/mL. Prior to the challenge, the mice were anesthe-
tized via intraperitoneal injection of avertin (250 mg/kg).
The mice were then intratracheally challenged with
40 μL of P. aeruginosa PAK. Whole blood and lung tis-
sue samples were collected 24 h after stimulation. The
lung tissue biopsies were fixed using 4% buffered forma-
lin and embedded in paraffin for hematoxylin and eosin
(HE) staining. For survival studies, the mice were ob-
served regularly over the subsequent 1 d after challenged
with PAK. Survival was monitored every 4 h and number
of deaths in all the groups were recorded. After P. aeru-
ginosa PAK infection, each mouse was given ad libitum
access to food and water. Data was plotted on Kaplan
Meir’s survival curve using Prism 5.0 software (Graph-
Pad software Inc., San Diego, CA, USA).
Measurement of proinflammatory cytokines
Commercially available enzyme-linked immunosorbent
assay (ELISA) kits (Pierce/Endogen, Rockford, IL, USA)
were used to measure the levels of IL-6, IL-8 and TNF-α
in serum. The absorbance at 450 nm of each of the sam-
ples was measured using a Bio-Rad Model 680 micro-
plate reader. The levels of IL-6, IL-8, and TNF-α were
determined based on standard curves and expressed as
pg/mL. Similarly, the levels of IL-6 and IL-8 in super-
natant were measured via this method.
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were purchased
from American Type Culture Collection (Rockville, MD,
USA). HEK 293 cells were grown to confluence in 96-well
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DMEM (H) medium supplemented with 10% fetal bovine
serum.
HEK 293 cells were co-transfected with the NF-κB lucif-
erase reporter plasmid PGL4.32 (Promega, WI, USA) and
the Renilla luciferase reporter vector plasmid pRL-TK
(Promega) at 100 and 9.6 ng per well, respectively. Trans-
fection was performed for 24 h using Lipofectamine 2000
according to the manufacturer’s instructions. The medium
was replaced with fresh serum-free medium 24 h prior to
experimentation. The cells were pretreated with the drug
1 h prior to TNF-α stimulation (10 ng/mL) for 6 h.
Dual-luciferase assay
After the cells had been stimulated, HEK 293 cells were
washed, lysed, and assayed for luciferase activity using a
dual-luciferase reporter assay system (Promega) accord-
ing to the manufacturer’s instructions. The relative lu-
ciferase activity was calculated by normalizing the firefly
luciferase activity against that of the internal control
(Renilla luciferase).
UPLC/Q-TOF MS analysis and sample preparation for
activity assays
A Waters Acquity UPLC system (Waters Co., USA)
equipped with a photodiode array detector (DAD) and a
Waters Q/TOF Premier Mass Spectrometer with an
electrospray ionization system (Waters MS Technolo-
gies, Manchester, UK) were used for sample analysis.
The data acquisition was supported by MassLynx V4.1
software (Waters Co., USA). The separations were per-
formed using a Waters Acquity UPLC BEH C18 column
(2.1 mm × 100 mm, 1.7 μm) at 30°C. The mobile phase
was acetonitrile (A)/ water containing 1% formic acid
(B) at a flow rate of 0.4 mL/min, and a gradient was per-
formed as follows: 0–3 min, A from 5% to 10%; 3–
10 min, A from 10% to 20%; 10–14 min, A from 20% to
50%; 14–16 min, A from 50% to 95%. The compounds
were detected via DAD scanning from 200 nm to
400 nm. The sample injection volume for analysis was
5 μL. The ESI-MS spectra were acquired in the negative
and positive ion modes. The conditions for ESI-MS ana-
lysis were as follows: the capillary voltage was set at
2.5 kV, the sample cone voltage was set at 30 V, the des-
olvation gas flow rate was set at 600 L/h at a desolvation
temperature of 300°C, the cone gas flow rate was set at
50 L/h, and the source temperature was 100°C. The Q/
TOF Premier acquisition rate was 0.1 s with a 0.02 s
inter-scan delay. The MS spectra are acquired from 50
to 1500 Da. Leucine-enkephalinamide acetate (LEA) was
used as the lock mass (m/z 555.2931 in ESI + mode and
553.2775 in ESI- mode) at a concentration of 200 ng/mL
and a flow rate of 0.2 μL/min. MS/MS analysis was per-
formed to calculate the mass fractions of the target ions.For sample preparation, mass spectrometry was not per-
formed, and the fractions were collected from the outlet
of the DAD into a 96-deep-well plate every 0.5 min. Then,
the solvent was evaporated until dryness in a vacuum dry-
ing oven. The residues were dissolved in 100 μL of cell
culture medium for further bioactivity assays.Statistical analysis
Statistical analysis was performed using SPSS software, and
the data were expressed as the means ± SEM. Multiple
comparisons were performed using ANOVA followed by
Bonferroni post hoc analysis. For single comparisons, sig-
nificant differences between the means were determined
using Student’s t test. P < 0.05 was considered to be statisti-
cally significant.Results and discussion
Effect of RM on lung infection induced by the
P. aeruginosa PAK strain
The P. aeruginosa PAK strain was introduced to estab-
lish a mouse inflammation model. The survival rate was
measured 4 h, 8 h, 12 h, 16 h, 20 h and 24 h after treat-
ment with the P. aeruginosa PAK strain. The survival
curve of the mice is presented in Figure 1A. Within
24 h of infection, the survival rate of the mice was only
20% in the model group, compared to 30%, 70% and
80% in the low, middle and high dose RM groups, re-
spectively. No death was observed in the positive con-
trol group. These results suggest that RM exerts a
protective effect against P. aeruginosa PAK strain lung
infection.
Pathologic sections of lung tissue are presented in
Figure 1B. Compared to the structural integrity of the lung
tissue from the control group, the lung sections from the
model group displayed a widened alveolar septum, capillary
congestion, and inflammatory cell infiltration around the
plasma vessels. This result indicated that the infection
model was successfully established. The inflammatory infil-
trates were significantly alleviated in the high dose RM
group, with less neutrophil recruitment and reduced histo-
logical injury. Histopathological evaluation of inflammation
revealed that RM exerted anti-inflammatory effects on the
mouse lung infection model.
Furthermore, the levels of the inflammatory cytokines
IL-6, IL-8 and TNF-α in serum samples from the mice
were determined via ELISA. As shown in Figure 1C, the
levels of IL-6, IL-8 and TNF-α in the model group were
significantly higher (more than control) (p < 0.001).
Compared to the model group, the levels of IL-6, IL-8 and
TNF-α were significantly decreased in both the middle
and high dose RM groups (p < 0.001 in TNF-α, p<0.01 in
IL-6 and IL-8 of RM-H, p<0.01 in TNF-α, p<0.05 in IL-6
of RM-M). These results demonstrated that RM treatment
Figure 1 Effect of RM on lung infection induced by the P. aeruginosa PAK strain. (A) The survival rate of mice treated with RM or Cef upon
challenge with P. aeruginosa. The survival rate was assessed for 24 h; (B) lung tissue pathology slices (the light microscopic images were captured
at 100× magnification); (Control) control group, (Model) model group, (Cef) positive control group, (RM-H) high dose RM group, (RM-M) middle
dose RM group,(RM-L) low dose RM group. Comparing with the control group, obvious inflammatory cell infiltration in mucosa and submucosa
in model group; (C) effects of RM on the production of TNF-α, IL-6, IL-8 in mouse serum.Value were expressed as the mean ± SEM (n = 6).
*p < 0.05, **p < 0.01,***p<0.001, compared to the model group (,). ###p<0.001 compared to the control group.
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tory cytokines by P. aeruginosa.
Effects of the BUE of RM on NF-κB activity
The effects of the different extracts of RM on TNF-α-
stimulated NF-κB activity in HEK 293 cells are presented in
Figure 2. Dex was used as positive control for NF-κB activ-
ity. The crude drug concentration of RM is 100 mg/mL ofthe various extracts. As a result, Dex (10−5 mol/L) and the
BUE of RM significantly inhibited TNF-α-induced NF-κB
production (Figure 2), indicating that the BUE extract repre-
sents a source of potential NF-κB inhibitors. Although EAE
also weakly inhibited NF-κB activity, the BUE extract was
used for the further identification of RM compounds via
UPLC-Q/TOF MS analysis and bioactivity detection due to
its greater potential for NF-κB inhibition.
Figure 2 Effects of the five extracts from RM on the level of NF-κB activity in TNF-α-stimulated HEK 293 cells.
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The optimal UPLC/Q-TOF-MS method was performed on
the BUE of RM. The column effluent was split 1:9 after
substance separation. One part was directed toward Q-
TOF-MS analysis, and the others were directed toward
diode array detection. The total ion current chromatograms
in the positive ion mode are shown in Figure 3B. [M+H]+
ions were recorded with as much relevant information as
possible to confirm the molecular weight, and the structure
of all of the constituents were deduced based on their exact
molecular weight, which was compared with the literatureFigure 3 UPLC/Q-TOF MS and bioactivity analysis of the BUE of RM. (
in the positive ESI mode; and (C) the chromatogram of the NF-κB activity d
NF-κB inhibition. The peak values are consistent with those reported in Tabdata and the natural products information reported in [30].
The MS/MS fragments and the retention time verified the
conclusions. Some peaks that had the same protonated
molecules in the MS spectra and similar fragment ions in
the MS/MS spectra could be distinguished and identified
due to their different retention behaviors. In the present
study, peak 1 at 2.23 min was chosen to demonstrate the
identification approach that was taken. The base peak in
the positive ESI mode was m/z 476.1713, which was con-
firmed to be the [M+H]+. The elemental and possible mo-
lecular compositions (C24H29NO9) were deduced based onA) UPLC/UV chromatograms of the BUE of RM; (B) TIC chromatogram
etected via the dual-luciferase reporter assay system to determine
le 1.
Table 1 The information about formula, maximum absorption wavelength, retention time, product ions and the
identification results for the bioactive compounds in RM
Peak no. tR (min) UV (λmax) Identification Composition MW Mode MS
2
1 2.23 203,283 N-norsinoacutin-β-D
-glucopyranoside
C24H29NO9 475.1842 Pos 476[M + H]
+, 314[M + H-C6H10O5]
+,
136[ M + H-C6H10O5-NC6H12O5]
+
2 2.89 201,280 6-O-methyl-laudanosoline −13-O-
glucopyranoside
C24H31NO9 477.1999 Pos 478[M + H]




3 3.60 203,251 sinomenine C19H23NO4 329.1627 Pos 330[M + H]




4 3.77 226,286 norsinoacutin C18H19NO4 313.1314 Pos 314[M + H]
+, 299[M + H-NH]+,
269[M + H-NH-CH2O]
+









7 8.39 196,232,281 dauricinoline C37H42N2O6 610.3042 Pos 611[M + H]
+, 580[M + H-CH3O]
+ ,
388[M + H-CH3O-C11H14 NO2]
+
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tions that were retrieved from the fragmentation pathways
were consistent with the literature [31]. Peak 1 was thus
determined to correspond to N-norsinoacutin-β-D-gluco-
pyranoside. Similarly, based on the fragmentation pathway
and high-resolution mass to four decimal places, the other
constituents were identified. The detailed results and struc-
tures of the seven candidate compounds are presented in
Table 1.Figure 4 Chemical structures of the bioactive compounds in RM.Identification on NF-κB inhibitors in the BUE of RM based
on bioactivity analysis
Following UPLC/diode array detection analysis (Figure 3A),
90% of the column effluents were collected as 0.5 min frac-
tions for the bioactivity assay using the dual-luciferase
reporter assay system. Each of the 36 fractions was evalu-
ated for their effect on NF-κB activity (Figure 3C). Seven
candidate compounds (Peaks 1 to 7) displayed potential
NF-κB inhibition that was two times higher than the blank.
Figure 5 Confirmation of the effects by potential NF-kB inhibitors. A: Effects of the potential NF-kB inhibitors on the NF-kB expression.
B and C: IL-6 and IL-8 expression in TNF-α induced BEAS-2B cells, respectively. Each bar represents the mean + SEM; n = 4 for each group.
(1: N-norsinoacutin-β-Dglucopyranoside; 2: 6-O-methyl-laudanosoline-13-O-glucopyranoside; 3: sinomenine; 4: norsinoacutin; 5: magnoflorine;
6: laurifloline; 7: dauricinoline). *p < 0.05, **p < 0.01, ***p < 0.001 compared to the model group. ##p < 0.01 compared to the control group.
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are presented in Figure 4. The potential NF-κB inhibitors
include: sinomenine, norsinoacutin, magnoflorine, N-
norsinoacutin-β-D-glucopyranoside, dauricinoline. lauriflo-
line and 6-O-methyl-laudanosoline-13-O-glucopyranoside,
There was a major peak between peaks 6 and 7, which was
deduced as menisperine based on UPLC/Q-TOF MS. How-
ever, in our study it did not display an inhibitory effect on
NF-κB activity.
Confirmation of the bioactivity of the NF-κB inhibitors
in RM
The activities of the bioactive compounds (100 μmol/L) in
RM were evaluated using the dual-luciferase reporter assay
system. As shown in Figure 5A, Dex (10 μmol/L) and the
seven potential NF-κB inhibitors (ingredients of RM)
displayed significant NF-κB inhibitory effects (p < 0.05)
compared to the model group. Especially, sinomenine,
magnoflorine and laurifloline (p < 0.001) displayed highly
significant inhibition. Because NF-κB transcription factors
synergistically activate transcription of the inflammatory cy-
tokines IL-6 and IL-8, the anti-inflammatory effect of these
seven ingredients on IL-6 and IL-8 were further evaluated
[32]. As shown in Figure 5B, IL-6 expression was reduced
by six of the compounds (p < 0.05), highly significantly by
laurifloline and sinomenine (p < 0.001); however, norsinoa-
cutin displayed no significant IL-6 inhibition based on our
assay. For IL-8, as shown in Figure 5C, sinomenine, norsi-
noacutin, magnoflorine and laurifloline demonstrated an
inhibitory effect (p < 0.05), but the other three compounds
did not display an inhibitory effect. Dex (10 μmol/L), the
positive control, significantly inhibited both IL-6 (p < 0.001)
and IL-8 expression (p < 0.05). The results further con-
firmed the anti-inflammatory effects of the seven com-
pounds as NF-κB inhibitors in RM.
Previous studies have demonstrated that magnoflorine
can increase the phagocytosis of neutrophils at a concentra-
tion of 0.5 μg/mL in vitro, suggesting that magnoflorine ex-
erts significant anti-inflammatory effects [33]. Additionally,
sinomenine has been used clinically to treat rheumatoid
arthritis. A systematic review and meta-analysis revealed
that sinomenine treatment can significantly decrease
rheumatoid factor levels in patients [34]. IL-6 gene expres-
sion is also significantly diminished by treatment with
1 mmol/L sinomenine for 48 h based on RT-PCR analysis,
suggesting an anti-inflammatory effect of sinomenine [35].
Consistent with a previous report [36], we demonstrated
the anti-inflammatory effects of magnoflorine and sinome-
nine, both of which significantly reduced the expression of
IL-6 and IL-8. This study is the first to report that 6-O-
methyl-laudanosoline-13-O-glucopyranoside, norsinoacutin,
laurifloline, dauricinoline and N-norsinoacutin-β-D-gluco-
pyranoside inhibit the activation of NF-κB. The NF-κB pro-
tein is a transcription factor that enhances the transcriptionof a variety of genes, including cytokines, growth factors, ad-
hesion molecules and immunoreceptors [37]. Upon activa-
tion, IκB is phosphorylated and degraded, leading to the
activation of NF-κB, further increasing the expression of in-
flammatory cytokines [38,39]. Norsinoacutin did not display
significant IL-6 inhibition, and 6-O-methyl-laudanosoline-
13-O-glucopyranoside, dauricinoline and N-norsinoacutin-
β-D-glucopyranoside did not display an inhibitory effect on
IL-8 expression in the present study. However, these com-
pounds may act on other cytokines, which require verifica-
tion in further experiments.
Conclusions
Our results revealed that RM could contribute to the allevi-
ation of inflammation in mice subjected to acute lung infec-
tion induced by the P. aeruginosa PAK strain. UPLC-Q/
TOF MS coupled with a luciferase reporter assay was uti-
lized to screen for and identification the NF-κB inhibitors
that may be responsible for the anti-inflammatory effects of
RM. Consequently, seven alkaloids were characterized as
NF-κB inhibitors. Among these compounds, to the best of
our knowledge, this is the first report that the alkaloids N-
norsinoacutin-β-D-glucopyranoside, 6-O-methyl-laudano-
soline-13-O-glucopyranoside, laurifloline, dauricinoline and
norsinoacutin interact with NF-κB. Furthermore, IL-6 and
IL-8 activity assays confirmed the anti-inflammatory effects
of these seven bioactive alkaloids. This study identified the
NF-κB inhibitory compounds in RM and provided useful
results for further investigation of its anti-inflammatory ef-
fects at the molecular level.
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